Assessment of novel combinations of biomarkers for the detection of XXXX .

@entity1 @entity5 @entity787 @entity1442 @entity14
BACKGROUND: @entity1 with @entity14 often present with @entity1442 and concomitant poor prognosis. The best known serum biomarker, @entity787 ( @entity787 ) is not recommended for screening because of its limited specificity and sensitivity. A number of other circulating proteins have been suggested to be diagnostically useful but individually none of these has proved to be of sufficient sensitivity or specificity to establish a role in routine clinical practice. Here, we test the hypothesis that combining several of these biomarkers will improve diagnostic efficacy. METHODS: To select the markers for our model we screened @entity787 and 26 other candidate biomarkers. Four candidates were selected and their concentrations determined in the serum of 239 @entity1 (106 @entity14 @entity1 and 133 non- @entity5 subjects). RESULTS: Class prediction models based on @entity787 , DR-70 and sCD26 produced a modest increase in detection accuracy over @entity787 alone, particularly for early stage @entity5 . The sensitivity and specificity required for a clinically useful test was not reached. CONCLUSION: It is unlikely that a biomarker panel comprised of the currently available serum markers will generate a clinically useful diagnostic test for @entity14 . Our findings reiterate the urgent need to discover novel biomarkers for the detection of @entity14 .
